Cover Image
市場調查報告書

GlaxoSmithKline plc:開發中產品分析

GlaxoSmithKline Plc - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 271848
出版日期 內容資訊 英文 406 Pages
訂單完成後即時交付
價格
Back to Top
GlaxoSmithKline plc:開發中產品分析 GlaxoSmithKline Plc - Product Pipeline Review - 2016
出版日期: 2016年02月29日 內容資訊: 英文 406 Pages
簡介

GlaxoSmithKline plc(GSK)是全球數一數二的研究開發型製藥、醫療保健企業。提供感染疾病,氣喘,心血管系統,心理健康,消化器官系統等各種疾病的治療用醫藥品。

本報告提供GlaxoSmithKline plc的治療用開發中產品之開發情形調查分析,提供您研究·開發概要,開發中產品概要,臨床實驗的各階段產品概要,藥物簡介,開發平台分析,企業資料等相關的系統性資訊。

目錄

GlaxoSmithKline plc概要

GlaxoSmithKline plc - 研究·開發概要

  • 主要治療領域

GlaxoSmithKline plc - 開發平台檢驗

  • 開發中產品:各開發階段
  • 開發中產品 - 單獨療法
  • 開發中產品 - 聯合治療
  • 開發中產品 - 聯盟產品
  • 開發中產品 - 轉出授權產品

GlaxoSmithKline plc - 開發中產品的概要

  • GSK-257049
  • GSK-2696273
  • meningococcal meningitis serotype B vaccine
  • mepolizumab
  • (fluticasone furoate + vilanterol trifenatate)
  • (fluticasone furoate + umeclidinium bromide + vilanterol trifenatate)
  • albiglutide
  • alitretinoin
  • ambrisentan
  • belimumab
  • bupropion hydrochloride ER
  • ebola strain zaire vaccine
  • fluticasone furoate
  • GSK-1437173A
  • GSK-2132231A
  • KD-295
  • losmapimod
  • measles strain schwarz + mumps strain RIT 4385 + rubella strain wistar RA 27/3 vaccine
  • ofatumumab
  • recMAGE-A3 + AS15
  • retosiban
  • tafenoquine succinate
  • vilanterol trifenatate
  • zanamivir
  • (fluticasone furoate + levocabastine hydrochloride)
  • afuresertib hydrochloride
  • batefenterol
  • CAD-106
  • camicinal
  • danirixin
  • daprodustat
  • fluticasone furoate + umeclidinium bromide
  • gepotidacin mesylate
  • GSK-1070806
  • GSK-2189242A
  • GSK-2231392A
  • GSK-2245035
  • GSK-2256098
  • GSK-2269557
  • GSK-2302032A
  • GSK-2330672
  • GSK-239512
  • GSK-2586881
  • GSK-2696274
  • GSK-2696275
  • GSK-2789869A
  • GSK-2798745
  • GSK-2830929A
  • GSK-2830930A
  • GSK-2838504-A
  • GSK-2862277
  • GSK-2890457
  • GSK-3003891A
  • GSK-3196165
  • GSK-598809
  • GSK-692342
  • GSK-732462
  • GSK-933776
  • levocabastine hydrochloride
  • malaria vaccine
  • mapatumumab
  • maribavir
  • meningococcal serotypes A, B, C, Y and W-135 (pentavalent) vaccine
  • Nimenrix
  • otelixizumab
  • ozanezumab
  • ProCvax
  • respiratory syncytial virus vaccine
  • rilapladib
  • streptococcal pneumoniae vaccine
  • streptococcus serogroup B (trivalent) vaccine
  • trametinib dimethyl sulfoxide + dabrafenib mesylate + panitumumab
  • trametinib dimethyl sulfoxide + uprosertib
  • umeclidinium bromide
  • afuresertib hydrochloride + trametinib dimethyl sulfoxide
  • GSK-2302025A
  • GSK-2636771
  • GSK-525762
  • HIV strains C1086, TV1 (bivalent) vaccine
  • pazopanib hydrochloride + pembrolizumab
  • TDEN-PIV
  • (amlodipine besylate + rosuvastatin calcium)
  • (candesartan cilexetil + hydrochlorothiazide) 、等

GlaxoSmithKline plc - 開發平台分析

  • 開發中產品:標的別
  • 開發中產品:各給藥途徑
  • 開發中產品:各分子類型
  • 開發中產品:各作用機制

GlaxoSmithKline plc - 開發中產品的最新趨勢

GlaxoSmithKline plc - 暫停的計劃

GlaxoSmithKline plc - 中止的開發中產品

  • 開發中止的開發中產品簡介

GlaxoSmithKline plc - 企業發表

GlaxoSmithKline plc - 所在地與子公司

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07970CDB

Summary

Global Markets Direct's, 'GlaxoSmithKline Plc - Product Pipeline Review - 2016', provides an overview of the GlaxoSmithKline Plc's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by GlaxoSmithKline Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of GlaxoSmithKline Plc
  • The report provides overview of GlaxoSmithKline Plc including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses GlaxoSmithKline Plc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features GlaxoSmithKline Plc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate GlaxoSmithKline Plc's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for GlaxoSmithKline Plc
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding GlaxoSmithKline Plc's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • GlaxoSmithKline Plc Snapshot
    • GlaxoSmithKline Plc Overview
    • Key Information
    • Key Facts
  • GlaxoSmithKline Plc - Research and Development Overview
    • Key Therapeutic Areas
  • GlaxoSmithKline Plc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • GlaxoSmithKline Plc - Pipeline Products Glance
  • GlaxoSmithKline Plc - Late Stage Pipeline Products
  • GlaxoSmithKline Plc - Clinical Stage Pipeline Products
  • GlaxoSmithKline Plc - Early Stage Pipeline Products
  • GlaxoSmithKline Plc - Unknown Stage Pipeline Products
  • GlaxoSmithKline Plc - Drug Profiles
    • gepirone hydrochloride ER
    • GSK-257049
    • GSK-2696273
    • mepolizumab
    • melanoma lysate vaccine
    • (fluticasone furoate + umeclidinium bromide + vilanterol trifenatate)
    • (fluticasone furoate + vilanterol trifenatate)
    • (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine
    • albiglutide
    • ambrisentan
    • AS15 + recMAGE-A3
    • belimumab
    • bupropion hydrochloride ER
    • Ebola [Zaire] vaccine
    • fluticasone furoate
    • GSK-1437173A
    • inotersen sodium
    • KD-295
    • losmapimod
    • meningococcal [serotype B] vaccine
    • retosiban
    • tafenoquine succinate
    • vilanterol trifenatate
    • zanamivir
    • (batefenterol succinate + fluticasone furoate)
    • (fluticasone furoate + levocabastine hydrochloride)
    • alitretinoin
    • batefenterol
    • CAD-106
    • camicinal
    • dabrafenib mesylate + panitumumab + trametinib dimethyl sulfoxide
    • danirixin
    • daprodustat
    • fluticasone furoate + umeclidinium bromide
    • gepotidacin mesylate
    • group B Streptococcus (trivalent) vaccine
    • GSK-2189242A
    • GSK-2231392A
    • GSK-2245035
    • GSK-2256098
    • GSK-2269557
    • GSK-2302032A
    • GSK-2315698 + GSK-2398852
    • GSK-2330672
    • GSK-2339345
    • GSK-239512
    • GSK-2586881
    • GSK-2696274
    • GSK-2696275
    • GSK-2789869A
    • GSK-2830930A
    • GSK-2838504A
    • GSK-2862277
    • GSK-3003891A
    • GSK-3196165
    • GSK-3277511A
    • GSK-692342
    • GSK-933776
    • GVXNSD-133
    • hepatitis C vaccine 1
    • malaria vaccine
    • mapatumumab
    • maribavir
    • meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine
    • otelixizumab
    • respiratory syncytial virus vaccine
    • rilapladib
    • Streptococcal pneumonia vaccine 3
    • umeclidinium bromide
    • GSK-2302025A
    • GSK-2636771
    • GSK-525762
    • HIV [strains C1086 + TV1] (bivalent) vaccine
    • pazopanib hydrochloride + pembrolizumab
    • TDEN-PIV
    • (amlodipine besylate + rosuvastatin calcium)
    • (candesartan cilexetil + hydrochlorothiazide)
    • (diphtheria + pertussis (acellular) + tetanus) vaccine
    • 1790GAHB
    • EcoXyn-4V
    • epelsiban besylate
    • FP-1039
    • GSK-1940029
    • GSK-2130579A
    • GSK-2241658A
    • GSK-2256294
    • GSK-2330811
    • GSK-2618960
    • GSK-2646264
    • GSK-2654909A
    • GSK-2654911A
    • GSK-2789868A
    • GSK-2798745
    • GSK-2800528
    • GSK-2816126
    • GSK-2831781
    • GSK-2849330
    • GSK-2857916
    • GSK-2878175
    • GSK-2879552
    • GSK-2881078
    • GSK-2981278
    • GSK-2981710
    • GSK-2982772
    • GSK-3008348
    • GSK-3117391
    • GSK-3174998
    • GSK-3206640A
    • GSK-3206641A
    • GSK-3389245A
    • hepatitis C vaccine 2
    • HIV vaccine 1
    • HIV vaccine 5
    • IMP-731
    • influenza [strain A/H5N1] vaccine
    • influenza vaccine 2
    • montelukast sodium
    • omipalisib
    • oxytocin
    • RSV-001
    • Staphylococcus aureus vaccine
    • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine
    • BLyS-gel
    • Cellular Immunotherapy to Target Flt3L for Autoimmune Myocarditis
    • Gene Therapy to Activate Lysyl Hydroxylase-3 for Recessive Dystrophic Epidermolysis Bullosa
    • GSK-030
    • GSK-1795091
    • GSK-2041706
    • GSK-214096
    • GSK-2225745
    • GSK-2394002
    • GSK-2656157
    • GSK-2795039
    • GSK-2820151
    • GSK-3039294
    • GSK-3277509A
    • GSK-3277510A
    • GSK-3326595
    • GSK-3359609
    • GSK-6288B
    • GSK-8853
    • GSKJ-4
    • GW-610742
    • HIV vaccine 2
    • influenza vaccine
    • marburg vaccine
    • meningococcal vaccine 2
    • Monoclonal Antibody Conjugate for Oncology
    • raxibacumab
    • Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis
    • Small Molecule 1 for Malaria
    • Small Molecule 1 to Inhibit Histone Methyltransferases for Cancer
    • Small Molecule 2 for Malaria
    • Small Molecule 2 for Tuberculosis
    • Small Molecule 2 to Inhibit Histone Methyltransferases for Cancer
    • Small Molecule 3 to Inhibit Histone Methyltransferases for Cancer
    • Small Molecule for Hypertension and Insulin Resistance
    • Small Molecule to Activate AMPK for Type 2 Diabetes
    • Small Molecule to Agonize S1P1 for Multiple Sclerosis
    • Small Molecules to Inhibit InhA for Tuberculosis
    • Small Molecules to Inhibit ROR gamma-t for Multiple Sclerosis and Rheumatoid Arthritis
    • staphylococci aureus vaccine
    • Streptococcal pneumonia vaccine
    • TC-2153
    • tuberculosis vaccine
    • Vaccine for Alzheimer's Disease
    • Vaccine for Cancer
    • bacterial vaccine
    • bacterial vaccine 2
    • Drug for Chronic Liver Disease
    • Drugs to Antagonize T-Cell Receptor for Oncology
    • Drugs to Inhibit Kynurenine 3-Monooxygenase for Acute Pancreatitis
    • GSK-137647A
    • GSK-343
    • GSK-5959
    • GSKJ-1
    • Proteins for Musculoskeletal Disorders
    • Pseudomonas aeruginosa vaccine
    • Small Molecule for Tuberculosis
    • Small Molecule to Antagonize FFA4 for Undisclosed Indication
    • Small Molecule to Inhibit Histone Deacetylases for Oncology
    • Small Molecules for HIV-1 Infection
    • Small Molecules for Tuberculosis
    • Small Molecules for Undisclosed Indication
    • Small Molecules to Antagonize Folate Receptor for Tuberculosis
    • Small Molecules to Inhibit ATPase family AAA Domain-Containing Protein 2 for Oncology
    • Small Molecules to Inhibit Falcipain for Malaria
    • Small Molecules to Inhibit Leucyl-tRNA Synthetase for Tuberculosis
    • Small Molecules to Inhibit RNA Polymerase for Hepatitis C
    • (paratyphoid + typhoid) vaccine
  • GlaxoSmithKline Plc - Pipeline Analysis
    • GlaxoSmithKline Plc - Pipeline Products by Target
    • GlaxoSmithKline Plc - Pipeline Products by Route of Administration
    • GlaxoSmithKline Plc - Pipeline Products by Molecule Type
    • GlaxoSmithKline Plc - Pipeline Products by Mechanism of Action
  • GlaxoSmithKline Plc - Recent Pipeline Updates
  • GlaxoSmithKline Plc - Dormant Projects
  • GlaxoSmithKline Plc - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • GlaxoSmithKline Plc - Company Statement
  • GlaxoSmithKline Plc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • GlaxoSmithKline Plc - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • GlaxoSmithKline Plc, Key Information
  • GlaxoSmithKline Plc, Key Facts
  • GlaxoSmithKline Plc - Pipeline by Indication, 2016
  • GlaxoSmithKline Plc - Pipeline by Stage of Development, 2016
  • GlaxoSmithKline Plc - Monotherapy Products in Pipeline, 2016
  • GlaxoSmithKline Plc - Combination Treatment Modalities in Pipeline, 2016
  • GlaxoSmithKline Plc - Partnered Products in Pipeline, 2016
  • GlaxoSmithKline Plc - Partnered Products/ Combination Treatment Modalities, 2016
  • GlaxoSmithKline Plc - Out-Licensed Products in Pipeline, 2016
  • GlaxoSmithKline Plc - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • GlaxoSmithKline Plc - Pre-Registration, 2016
  • GlaxoSmithKline Plc - Filing rejected/Withdrawn, 2016
  • GlaxoSmithKline Plc - Phase III, 2016
  • GlaxoSmithKline Plc - Phase II, 2016
  • GlaxoSmithKline Plc - Phase I, 2016
  • GlaxoSmithKline Plc - IND/CTA Filed, 2016
  • GlaxoSmithKline Plc - Preclinical, 2016
  • GlaxoSmithKline Plc - Discovery, 2016
  • GlaxoSmithKline Plc - Unknown, 2016
  • GlaxoSmithKline Plc - Pipeline by Target, 2016
  • GlaxoSmithKline Plc - Pipeline by Route of Administration, 2016
  • GlaxoSmithKline Plc - Pipeline by Molecule Type, 2016
  • GlaxoSmithKline Plc - Pipeline Products by Mechanism of Action, 2016
  • GlaxoSmithKline Plc - Recent Pipeline Updates, 2016
  • GlaxoSmithKline Plc - Dormant Developmental Projects,2016
  • GlaxoSmithKline Plc - Discontinued Pipeline Products, 2016
  • GlaxoSmithKline Plc, Other Locations
  • GlaxoSmithKline Plc, Subsidiaries
  • GlaxoSmithKline Plc, Key Manufacturing Facilities

List of Figures

  • GlaxoSmithKline Plc - Pipeline by Top 10 Indication, 2016
  • GlaxoSmithKline Plc - Pipeline by Stage of Development, 2016
  • GlaxoSmithKline Plc - Monotherapy Products in Pipeline, 2016
  • GlaxoSmithKline Plc - Combination Treatment Modalities in Pipeline, 2016
  • GlaxoSmithKline Plc - Partnered Products in Pipeline, 2016
  • GlaxoSmithKline Plc - Out-Licensed Products in Pipeline, 2016
  • GlaxoSmithKline Plc - Pipeline by Top 10 Target, 2016
  • GlaxoSmithKline Plc - Pipeline by Route of Administration, 2016
  • GlaxoSmithKline Plc - Pipeline by Top 10 Molecule Type, 2016
  • GlaxoSmithKline Plc - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top